INTRODUCTION
============

It is controversial whether preoperative biliary drainage is necessary in patients with pancreatic head cancers with jaundice.[@ref1],[@ref2] Some reports have revealed that preoperative biliary drainage when waiting for curative surgery can increase biliary adverse events, whereas others have indicated the necessity of biliary drainage in the case of severe jaundice and neoadjuvant chemotherapy/neoadjuvant chemoradiotherapy (NAC/NACRT).[@ref3],[@ref4] NAC/NACRT for resectable or borderline resectable pancreatic cancers has recently been initiated to improve clinical outcomes in some institutions because curative resection followed by adjuvant chemotherapy cannot sufficiently improve the survival (5-year survival rate of \<6% in 2015).[@ref5] Some clinical studies have reported that NAC/NACRT is beneficial compared with up-front surgery for pancreatic cancer as well as other gastrointestinal cancers.[@ref6]

There have been many reports on biliary drainage for patients with unresectable pancreatic cancer, which have indicated that a metal stent (MS) is superior to a plastic stent (PS) in terms of patency;[@ref7] however, there have been few reports on biliary drainage for patients with pancreatic cancer during NAC/NACRT. A meta-analysis on preoperative biliary drainage with/without NAC/NACRT showed that the rates of endoscopic re-intervention before surgery and the occurrence rates of postoperative complications, especially pancreatic fistula, were higher in the PS group than in the MS group.[@ref8] For biliary decompression during NAC/NACRT, we also need to consider removability of a biliary stent (easier to remove PS than MS) and total stenting cost (cheaper single PS than single MS).

We also performed two multicenter prospective observational studies with NAC/NACRT: NAC with two cycles of S-1 for patients with resectable pancreatic cancer; NACRT with radiation and S-1 followed by three cycles of gemcitabine in cooperation with radiologists for patients with borderline resectable (locally advanced) pancreatic cancer. In these studies, some patients underwent biliary decompression with MS or PS for NAC/NACRT followed by pancreatoduodenectomy. Thus, we retrospectively performed a subanalysis of this population to clarify the clinical outcomes of biliary drainage with MS and PS during NAC/NACRT.

CASE REPORT
===========

From October 2013 to April 2016, 96 patients with pathologically diagnosed pancreatic cancer who gave informed consent were registered for NAC or NACRT studies conducted by Hokkaido Pancreatic Cancer Study Group (HOPS) (UMIN000013031/UMIN000012293). Of these, 29 patients who underwent biliary drainage with MS or PS before NAC/NACRT and subsequent pancreatoduodenectomy were analyzed.

Patients with resectable pancreatic cancer were registered in HOPS-R01, in which NAC with S-1 (80 mg/m^2^, twice daily) for two cycles (84 days) was performed. After NAC, patients underwent curative surgery within 6 weeks after last oral administration of S-1. Patients with borderline resectable pancreatic cancer based on National Comprehensive Cancer Network guidelines (2012, version 2) were registered in HOPS-BR01, in which NACRT with a total dose of 50.4 Gy in 28 fractions and S-1 (80 mg/m^2^, twice daily on radiation day alone) was continued for 1 month with subsequent chemotherapy with three cycles of gemcitabine (84 days). After NACRT, patients underwent curative surgery within 8 weeks after last administration of gemcitabine. Before NAC/NACRT, patients with total bilirubin \>2.0 mg/dL or \>3 times the aspartate aminotransferase/alanine aminotransferase value of the normal upper limit underwent endoscopic biliary stenting with MS or PS at the discretion of an endoscopist.

Recurrent biliary obstruction (RBO) after endoscopic biliary stenting was defined on the basis of the Tokyo criteria.[@ref9] Adverse events related to endoscopic biliary stenting were defined on the basis of a lexicon of American Society for Gastrointestinal Endoscopy.[@ref10] When NAC/NACRT could not be performed on the planned date due to adverse events and performed on another date, it was defined as NAC/NACRT delay. When NAC/NACRT was canceled due to adverse events or patient refusal, it was defined as NAC/NACRT discontinuation. Complications after curative surgery were evaluated and graded on the basis of the extended Clavien-Dindo classification.[@ref11] Postoperative pancreatic fistula was defined according to the International Study Group definition.[@ref12]

Unresectable conversion rate in NAC was eight out of 51 (16%) (8/49 \[16%\] after exclusion of ineligible 2 cases) and that in NACRT, 17 out of 45 (38%). Patient characteristics of the 29 patients are shown in [Table 1](#T1){ref-type="table"}. Twenty-two patients were classified as Union for International Cancer Control stage IIA and seven patients, as stage III. Further, 14 patients underwent NAC, and 15 patients underwent NACRT. For biliary decompression, MS and PS were placed in 17 and 12 patients, respectively. The details of MS/PS stent are indicated in [Table 1](#T1){ref-type="table"}.

RBO occurred in 11 patients, of which one patient was in the MS group and 10 patients including two migration cases were in the PS group. The occurrence rate of RBO was significantly higher in the PS group (83.3%) than in the MS group (6%) (p\<0.001) as well as the average stenting number per patient (MS/PS, 1.12/2.08) (p\<0.001). The log-rank test also revealed that the patency in the MS group was significantly higher than that in the PS group (not reached vs 63.5 days, p\<0.001) ([Fig. 1](#F1){ref-type="fig"}). There was no stenting-related adverse event which affected NAC/NACRT.

NAC/NACRT delay was observed in 35% of the patients in the MS group and 50% of the patients in the PS group; NAC/NACRT discontinuation, in 12% and 17%, respectively. Mean relative dose intensities of NAC and NACRT were respectively 87% and 98% (the first part with S-1 with radiotherapy) followed by 74% (the second part with gemcitabine) in total: 95% and 98% followed by 68% in the MS group, while 76% and 100% followed by 83% in the PS group.

The operative time in the MS group tended to be longer than that in the PS group (625 minutes vs 497 minutes, p=0.051), while operative blood loss, postoperative adverse event rates including postoperative pancreatic fistula and the distributions of Evans classification in both groups were not significantly different.

A multiple regression analysis for operative times was performed. Of the 10 factors (age, sex, final tumor size, Union for International Cancer Control stage, stent type, stent patency, RBO, neoadjuvant therapy, operative blood loss, and Evans classification), sex, stent type, neoadjuvant therapy, and operative blood loss significantly contributed to operative time (R[@ref2]=0.69) (regression coefficient±standard error, p-value: 0.061±0.0264, p=0.029; --0.0639±0.0261, p=0.023; --0.0985±0.0253, p\<0.001; 0.0000902±0.0000241, p=0.001).

DISCUSSION
==========

The present study revealed that MS is better than PS for biliary decompression during NAC/NACRT from the viewpoint of preventing RBO.

Many studies have revealed the superiority of MSs to PSs for stent patency in patients with both unresectable and resectable malignant distal biliary strictures, and this was compatible with our result.[@ref4],[@ref13]-[@ref15] This superiority may result from the larger diameter of MSs than that of PSs.

NAC/NACRT is becoming increasingly important for the improvement of clinical outcomes after the resection of pancreatic cancers. Some previous studies have indicated a better prognosis for pancreatic cancer patients who undergo NAC/NACRT[@ref16],[@ref17] than for those who do not, and some randomized controlled trials comparing NAC with NACRT and comparing NAC/NACRT with up-front surgery for pancreatic cancers are ongoing.[@ref18]-[@ref20] The roles of biliary decompression, drainage method, and choice of the biliary stent during NAC/NACRT are very significant during the preoperative period. The retrospective study by Tsuboi et al.[@ref21] revealed that MS implantation is effective for preoperative biliary drainage in pancreatic cancer cases treated with NAC because of the low rates of stent-related complications (0% vs 72.7%) and NAC delay (11.1% vs 81.8%).

How MS or PS pathologically affects the bile duct, vessels, duodenal mucosa, and the tissues around them during NAC/NACRT is unclear. According to some reports including operative and autopsy cases, remarkable collagenous reaction, inflammation, and epithelial atypia in the bile duct occur around uncovered MSs in patients with malignant biliary obstruction.[@ref22],[@ref23] Such pathological changes would occur in the case of NAC/NACRT with MSs and negatively affect the operative time and hemorrhagic volume during surgery. There have been some reports concerning the relationship between radiation and pathological response of organs, indicating that sclerosis and stricture can occur in the bile duct, whereas ulcer, bleeding, and perforation by ischemia can occur in the gastrointestinal tract.[@ref24],[@ref25] Thus, MS and radiation could synergistically cause pathological damage to the bile duct and duodenum in the radiation area, leading to perioperative bleeding and prolonged operative time. Meanwhile, some previous reports have indicated that preoperative placement of a MS does not affect clinical outcomes concerning the resection of pancreatic cancers, including adverse events during the perioperative period, and that MS is superior to PS with regard to preoperative stent patency.[@ref4],[@ref15] Thus, MS would be appropriate for preoperative biliary decompression during NAC/NACRT, although there has been no randomized controlled trial comparing MS with PS during NAC/NACRT.

There are some limitations to the present study. First, this was a retrospective, non-randomized study with an insufficient number of patients. Second, neoadjuvant therapy included both chemotherapy and chemoradiotherapy. Third, the size of PS was not unified.

In conclusion, MS would be better than PS from the viewpoint of preventing RBO, although MS would be similar to PS with regard to perioperative outcomes.
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Characteristics of the 29 Patients

  Characteristic                                                         All                                                                                  MS                                                                                 PS                                                                                  p-value (MS vs PS)
  ---------------------------------------------------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- --------------------
  No. of patients                                                        29                                                                                   17                                                                                 12                                                                                  \-
  Male/female                                                            13/16                                                                                8/9                                                                                5/7                                                                                 1.000
  Age, median (range), yr                                                67 (50--83)                                                                          66 (50--83)                                                                        68 (53--80)                                                                         0.824
  JPS stage (6th) I/II/III/IV                                            0/0/10/19                                                                            0/0/5/12                                                                           0/0/5/7                                                                             1.000
  UICC stage (7th) IIA/III                                               22/7                                                                                 12/5                                                                               10/2                                                                                0.665
  NAC/NACRT, mean RDI (%)                                                14/15 (87/98[\*](#t1fn2){ref-type="table-fn"}, 74[†](#t1fn2){ref-type="table-fn"})   8/9 (95/98[\*](#t1fn2){ref-type="table-fn"}, 68[†](#t1fn2){ref-type="table-fn"})   6/6 (76/100[\*](#t1fn2){ref-type="table-fn"}, 83[†](#t1fn2){ref-type="table-fn"})   \-
  Delay, %                                                               35                                                                                   50                                                                                 0.680                                                                               
  Discontinuation, %                                                     12                                                                                   17                                                                                 1.000                                                                               
  Final tumor size, median (range), mm[‡](#t1fn2){ref-type="table-fn"}   20 (11--40)                                                                          21 (14--40)                                                                        19 (11--28)                                                                         0.351
  RBO rate, % (migration no.)                                            38 (2)                                                                               6 (0)                                                                              83 (2)                                                                              \<0.001
  Stenting no. per patient, average (range)                              1.52 (1--3)                                                                          1.12 (1--2)                                                                        2.08 (1--3)                                                                         \<0.001
  Stenting cost per patient (US \$)                                      4,973[§](#t1fn2){ref-type="table-fn"}                                                5,700[§](#t1fn2){ref-type="table-fn"}                                              \-                                                                                  
  Stent diameter/no. of patients                                         10 mm/17                                                                             7 F/9, 8.5 F/ 2, 10 F/1                                                            \-                                                                                  
  Stent length 5/6/7/8 cm                                                1/13/0/3                                                                             4/0/8/0                                                                            \-                                                                                  
  Fully-/partially-/uncovered                                            5/12/0                                                                               \-                                                                                 \-                                                                                  
  ES operation +/--                                                      12/17                                                                                5/12                                                                               7/5                                                                                 0.148
  Stenting-related AE                                                    1                                                                                    1[ΙΙ](#t1fn2){ref-type="table-fn"}                                                 0                                                                                   1.000
  Operative procedure SSPPD/TP                                           17/0                                                                                 11/1                                                                               1.000                                                                               
  Operative time, median (IQR), min                                      625 (493--694)                                                                       497 (397--554)                                                                     0.051                                                                               
  Operative blood loss, median (IQR), mL                                 719 (430--1,150)                                                                     649 (301--927)                                                                     0.479                                                                               
  Postoperative AE, %                                                    47.1                                                                                 50                                                                                 1.000                                                                               
  Clavian-Dindo classification I/II/IIIa                                 3/3/2                                                                                0/2/4                                                                              0.353                                                                               
  Postoperative pancreatic fistula, no. (%)                              2 (11.8)                                                                             0                                                                                  0.498                                                                               
  Evans classification I/IIa/IIb/III                                     4/4/8/1                                                                              4/6/2/0                                                                            0.243                                                                               

MS, metal stent; PS, plastic stent; JPS, Japan Pancreas Society; UICC, Union for International Cancer Control; NAC, neoadjuvant chemotherapy; NACRT, neoadjuvant chemoradiotherapy; RDI, relative dose intensity; RBO, recurrent biliary obstruction; ES, endoscopic sphincterotomy; AE, adverse event; SSPPD, subtotal stomach-preserving pancreaticoduodenectomy; TP, total pancreatectomy; IQR, interquartile range.

First part with S-1 with radiotherapy; ^†^Second part with gemcitabine; ^‡^The size measured on contrast-enhanced computed tomography within 2 weeks before pancreatoduodenectomy; ^§^Theoretical cost calculated by stent value, stenting number, procedure and admission cost; ^ΙΙ^Abdominal pain after stenting. Categorical data were examined using the chi-square test. The Mann-Whitney U test was used to compare quantitative data.
